Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | SVP of Operations, CMO | July 27, 2020 | July 29, 2020 |
| iBio, Inc.IBIO, INC. · Entity 6906 | Chief Operating Officer | December 07, 2021 | March 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date July 27, 2020 · Filed July 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.16 · Expires 2026-08-03 | Direct | 0 |
Reported balance
After 2020-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-27 · Disposition to issuer · Disposed 5,357 · Balance 0 F1: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F2: This stock option award vested over three years, and the final one-third vested on August 3, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.44 · Expires 2027-02-24 | Direct | 0 |
Reported balance
After 2020-07-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-27 · Disposition to issuer · Disposed 2,407 · Balance 0 F1: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F4: This stock option award vested over three years, and the final one-third vested on February 24, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.10 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2020-07-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-27 · Disposition to issuer · Disposed 2,407 · Balance 0 F1: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F5: This stock option award vested over three years, and the final one-third vested on June 1, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.82 · Expires 2028-03-09 | Direct | 0 |
Reported balance
After 2020-07-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-27 · Disposition to issuer · Disposed 4,814 · Balance 0 F1: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F6: These options provide for vesting in three approximately equal annual installments beginning on March 9, 2018. Prior to July 27, 2020, all but 1,605 shares of the issuer's common stock underlying this stock option had vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.28 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2020-07-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-27 · Disposition to issuer · Disposed 4,814 · Balance 0 F1: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F7: These options provide for vesting in three approximately equal annual installments beginning on February 28. 2020. Prior to July 27, 2020, all but 3,210 shares of the issuer's common stock underlying this stock option had vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.56 · Expires 2030-07-26 | Direct | 6,423 |
Reported balance
After 2020-07-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-27 · Grant · Acquired 6,423 · Balance 6,423 F3: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F8: These options vest in full on the one year anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.56 · Expires 2030-07-26 | Direct | 2,140 |
Reported balance
After 2020-07-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-27 · Grant · Acquired 2,140 · Balance 2,140 F3: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F9: These options will vest in three approximately equal annual installments beginning on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020.
F2: This stock option award vested over three years, and the final one-third vested on August 3, 2020.
F3: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4.
F4: This stock option award vested over three years, and the final one-third vested on February 24, 2020.
F5: This stock option award vested over three years, and the final one-third vested on June 1, 2020.
F6: These options provide for vesting in three approximately equal annual installments beginning on March 9, 2018. Prior to July 27, 2020, all but 1,605 shares of the issuer's common stock underlying this stock option had vested.
F7: These options provide for vesting in three approximately equal annual installments beginning on February 28. 2020. Prior to July 27, 2020, all but 3,210 shares of the issuer's common stock underlying this stock option had vested.
F8: These options vest in full on the one year anniversary of the date of grant.
F9: These options will vest in three approximately equal annual installments beginning on the one-year anniversary of the date of grant.
iBio, Inc.
Report date December 07, 2021 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 271,757 |
Reported balance
After 2021-12-07 transaction · row 1
1 source rowRow 1 · 2021-12-07 · Sale · Disposed 37,243 · Balance 271,757 F1: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. F2: These shares were sold in a single transaction at a price of $0.6832 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc.
F2: These shares were sold in a single transaction at a price of $0.6832 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2021 Filed Mar 14, 2022 16:11 UTC | iBio, Inc. IBIO, INC. · Entity 6906 | SaleCommon Stock | 37,243 | $0.68 | $25,444.42 |
DisclosureSEC source: 0001104659-22-033319 · tm229111-1_4seq1.xml · nonDerivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,757 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs represent a contingent right to receive one share of common stock of iBio, Inc. F2 · price: These shares were sold in a single transaction at a price of $0.6832 per share. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:32 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001104659-21-109469 · tm2125787-3_4seq1.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-08-22 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 17:26 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option · Derivative | 465,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001104659-20-131634 · tm2037478d2_4.xml · derivative · entry 2 Maddux Randy Joe · CIK 0001683826 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,000 Underlying: Common Stock · 465,000 shares Expires 2030-11-30 F2 · derivative.exercise_date: The options vest as follows: (i) 25% of the options granted under the 2018 Plan will vest after one year of employment with the Company; and (ii) after one year of employment with the Company, 6.25% of the options granted will vest for each additional three (3) months of employment. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 17:26 UTC | iBio, Inc. IBIO · Entity 6906 | GrantCommon Stock | 309,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-131634 · tm2037478d2_4.xml · nonDerivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,000 F1 · shares: Consists of 309,000 shares of iBio, Inc. (the "Company") common stock , $0.001 par value per share (the "Common Stock") represented by 309,000 restricted stock units ("RSUs") granted under the Company's 2018 Omnibus Equity Incentive Plan, as amended (the "2018 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 309,000 RSUs start vesting pro rata on the (i) first anniversary of the grant date; (ii) second anniversary of the grant date; and (iii) third anniversary of the grant date. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 2,140 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000439 · maddux.xml · derivative · entry 7 Maddux Randy Joe · CIK 0001683826 · SVP of Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,140 Underlying: Common Stock · 2,140 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F9 · derivative.exercise_date: These options will vest in three approximately equal annual installments beginning on the one-year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 6,423 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000439 · maddux.xml · derivative · entry 6 Maddux Randy Joe · CIK 0001683826 · SVP of Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,423 Underlying: Common Stock · 6,423 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F8 · derivative.exercise_date: These options vest in full on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 4,814 | Not disclosed Strike: $21.28 | Not disclosed |
DisclosureSEC source: 0001019056-20-000439 · maddux.xml · derivative · entry 5 Maddux Randy Joe · CIK 0001683826 · SVP of Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,814 shares Expires 2029-02-28 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F7 · derivative.exercise_date: These options provide for vesting in three approximately equal annual installments beginning on February 28. 2020. Prior to July 27, 2020, all but 3,210 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 4,814 | Not disclosed Strike: $43.82 | Not disclosed |
DisclosureSEC source: 0001019056-20-000439 · maddux.xml · derivative · entry 4 Maddux Randy Joe · CIK 0001683826 · SVP of Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,814 shares Expires 2028-03-09 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F6 · derivative.exercise_date: These options provide for vesting in three approximately equal annual installments beginning on March 9, 2018. Prior to July 27, 2020, all but 1,605 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,407 | Not disclosed Strike: $30.10 | Not disclosed |
DisclosureSEC source: 0001019056-20-000439 · maddux.xml · derivative · entry 3 Maddux Randy Joe · CIK 0001683826 · SVP of Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,407 shares Expires 2027-06-01 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F5 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on June 1, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,407 | Not disclosed Strike: $27.44 | Not disclosed |
DisclosureSEC source: 0001019056-20-000439 · maddux.xml · derivative · entry 2 Maddux Randy Joe · CIK 0001683826 · SVP of Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,407 shares Expires 2027-02-24 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F4 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on February 24, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 5,357 | Not disclosed Strike: $41.16 | Not disclosed |
DisclosureSEC source: 0001019056-20-000439 · maddux.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · SVP of Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,357 shares Expires 2026-08-03 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F2 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on August 3, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| February 18, 2020 Filed Mar 19, 2020 18:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 134,800 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001019056-20-000242 · maddux_4.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · SVP Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,800 Underlying: Common Stock · 134,800 shares Expires 2030-02-17 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 17, 2021. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 20:54 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 122,359 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001019056-19-000616 · maddux_4.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · SVP Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,359 Underlying: Common Stock · 122,359 shares Expires 2029-10-31 F1 · derivative.exercise_date: The options vest on November 1, 2020, the one-year anniversary of the grant date. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:29 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 25,000 | $0.76 | $19,000.00 |
DisclosureSEC source: 0001019056-19-000487 · maddux_4.xml · nonDerivative · entry 1 Maddux Randy Joe · CIK 0001683826 · SVP Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Read SEC document |
| May 31, 2019 Filed Jun 7, 2019 15:18 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 20,000 | $0.73 | $14,600.00 |
DisclosureSEC source: 0001593968-19-001343 · primary_01.xml · nonDerivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000180 · maddux_4.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · SVP Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F1 · derivative.exercise_date: The options vest in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 18:28 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 5,000 | $2.37 | $11,850.00 |
DisclosureSEC source: 0001019056-18-001118 · white_4.xml · nonDerivative · entry 1 Maddux Randy Joe · CIK 0001683826 · SVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:39 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Options (Right to Buy) · Derivative | 67,400 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001019056-18-000437 · maddux_4.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2028-03-09 F1 · derivative.exercise_date: On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| November 15, 2017 Filed Dec 8, 2017 18:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 25,000 | $2.76 | $69,000.00 |
DisclosureSEC source: 0001019056-17-000796 · maddux_4.xml · nonDerivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| June 01, 2017 Filed Jun 1, 2017 21:40 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Option (right to buy) · Derivative | 33,700 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001019056-17-000548 · maddux_4.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,700 Underlying: Common Stock · 33,700 shares Expires 2027-05-31 F1 · date: The option grant was approved by a committee of Aptevo Therapeutics Inc.'s board of directors on February 22, 2017, subject to stockholder approval of the Amended and Restated 2016 Stock Incentive Plan (the "Plan") under which the option was granted. Aptevo Therapeutics Inc.'s stockholders approved the Plan on May 31, 2017. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 1, 2018. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 16:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 33,700 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001019056-17-000236 · maddux_4.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,700 Underlying: Common Stock · 33,700 shares Expires 2027-02-24 F1 · derivative.exercise_date: The options vest in three equal annual installments beginning on February 24, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.